Diligence memo · auto-generated · as of July 2, 2026
Revalia Bio, Inc.
Revalia Bio, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Revalia Bio, Inc. operates in Biotechnology, based in NEW HAVEN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Revalia Bio, Inc. has raised $12M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $12M on 2024-10-25.
Most recent recorded round closed around 2024-10-25.
Valuation (modeled)modeled
Provath models Revalia Bio, Inc. at approximately $55M (range $13M–$111M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.25× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era. Within the normal band (125% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 20 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 60% of Biotechnology peers (4293 compared).
Modeled value ranks above 48% of those peers.
Closest niche peers: GeoVax Labs, Inc., Cellinfinity Bio Holding Company, LLC, Adient Medical, Inc., Entegrion Inc, BCD Bioscience, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.